Chrna9 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CHRNA9 Gene | |
|---|---|
| Full Name | Cholinergic Receptor Nicotinic Alpha Subunit 9 |
| Chromosome | 17p13.2 |
| NCBI Gene ID | 55584 |
| OMIM | 605375 |
| Ensembl ID | ENSG00000174373 |
| UniProt ID | Q9GZZ3 |
| Associated Diseases | Auditory neuropathy spectrum disorder, Sensorineural hearing loss, Nicotinic acetylcholine receptor dysfunction |
CHRNA9 encodes the alpha9 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel expressed in the inner ear and various brain regions. The alpha9-containing receptors are involved in auditory function, vestibular processing, and cholinergic modulation of neuronal excitability. Dysfunction has been implicated in age-related hearing loss and may affect cholinergic signaling in neurodegenerative diseases.
The CHRNA9 gene encodes a protein involved in critical cellular processes in the nervous system. This gene product plays important roles in neuronal development, signal transduction, and cellular homeostasis.
Auditory neuropathy spectrum disorder, Sensorineural hearing loss, Nicotinic acetylcholine receptor dysfunction are associated with dysfunction in this gene. These conditions highlight the importance of proper CHRNA9 function in neuronal survival and brain homeostasis.
The diseases associated with CHRNA9 follow various inheritance patterns including autosomal recessive and autosomal dominant, depending on the specific mutation.
Expression of CHRNA9 is detected in various brain regions with particular enrichment in areas relevant to neurodegenerative processes. Studies using the Allen Brain Atlas show characteristic expression patterns in the cerebral cortex, hippocampus, and brainstem.
Understanding the role of CHRNA9 in neurodegeneration may lead to therapeutic interventions targeting the specific molecular pathways affected. Research directions include:
Ongoing research focuses on:
The study of Chrna9 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The CHRNA9 gene encodes the α9 subunit of nicotinic acetylcholine receptors (nAChRs). The α9 subunit is unique among nAChR subunits because it can form functional homomeric channels as well as heteromeric receptors with α10 subunits [1].
Key structural features:
α9-containing nAChRs exhibit distinctive pharmacological properties:
CHRNA9 is most highly expressed in the inner ear:
Functions in the ear:
In the brain, α9 nAChRs are expressed in:
CHRNA9 mutations cause auditory neuropathy spectrum disorder (ANSD):
While primarily associated with hearing disorders, CHRNA9 may play roles in:
Alzheimer's Disease
Parkinson's Disease
Age-Related Hearing Loss (Presbycusis)
| Compound | Mechanism | Development Status |
|---|---|---|
| Nicotine | Direct agonist | Research |
| Choline | Endogenous agonist | Research |
| PHA-543613 | Selective agonist | Preclinical |
Elgoyhen AB, Johnson DS, Boulter J, Vetter DE, Heinemann S. "Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells." Cell. 1994;79(4):705-715. DOI:10.1016/0092-8674(9490555-X ↩︎